No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy

(MedPage Today) -- Survival in metastatic non-small cell lung cancer (NSCLC) did not improve with the addition of the antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) to immunotherapy, a large randomized trial showed. Median progression...